

JOINT EVENT

14th International Conference on **Generic Drugs and Biosimilars**
&9th Global Experts Meeting on **Neuropharmacology**

November 15-16, 2018 | Berlin, Germany



Francois-Xavier Frapaise

F.-X. Frapaise Consulting, France

Patients education on biosimilars

Biography

Francois-Xavier Frapaise has over 30 years of international drug development, strategic planning and marketing experience at major pharmaceutical companies including Sanofi, Bayer, Boehringer, Merck and Abbott; he has held multiple C-level positions (CSO, CMO, CEO) in different Pharmacos in the US and Europe. He is currently heading Clinical Development, Medical Affairs and Pharmacovigilance at Merck KGaA Biosimilars Division; he has extensive experience of biosimilars development (Boehringer-Ingelheim, Pfenex); He has been the CSO and SVP of Optimer, has served as the CEO of Asphelia Pharmaceuticals, Inc. VP R&D and Corporate Officer of TAP, CMO of Ocera Therapeutics, VP of Scientific Affairs at Abbott International, Head of Medical Affairs at Bayer Europe, Medical Director at Bayer France, VP of R&D at Delagrange, Head of Anti-thrombotics Strategic Marketing at Sanofi, Medical Director at Choay. Frapaise holds an MD degree from Faculté de Médecine Paris and is a INSEAD alumni. Frapaise holds an academic position at the Thrombosis Research Center at the Loyola Medical Center in Maywood (IL).

xavierfrapaise@yahoo.com

Notes: